CT 388
Alternative Names: CT-388; RG-6640Latest Information Update: 22 May 2024
At a glance
- Originator Carmot Therapeutics
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides; Small molecules
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
- Phase I/II Type 2 diabetes mellitus
- Discontinued Fatty liver; Non-alcoholic steatohepatitis